Sanofi-aventis enters into Antibody Agreements with Dyax for the fully human monoclonal antibody DX-2240 and “Phage Display Technology”

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).